Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine

Phase 1 Completed 22 enrolled Wyeth is now a wholly owned subsidiary of Pfizer ViroPharma · collab

Non-randomizedParallel-groupOpen-label

Summary

To evaluate the potential pharmacokinetic (PK) interaction of multiple oral doses of HCV-796 and a single dose of desipramine when coadministered to healthy subjects.

Timeline

Start: 2007-06
Primary completion: 2007-08
Completion: 2007-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Desipramine	Small molecule	50 mg	Oral
Subject	NESBUVIR	Small molecule	500 mg	Oral

Indications

No indication recorded.